Atypical brain maturation in psychosis is associated with long-term cognitive decline and symptom progression

Claudio Alemán-Morillo[1], Natalia García-San-Martín[1], Richard AI Bethlehem[2], Lena Dorfschmidt[3,4], María Alemany-Navarro[5], Patricia Segura[1], Alessia Pasquini[1], Manuel Muñoz Caracuel[6], Manuel Canal Rivero[6], Jakob Seidlitz[3,4,7,8], Rosa Ayesa-Arriola[9], Javier Vázquez-Bourgon[9], John Suckling[10], Miguel Ruiz-Veguilla[6], Benedicto Crespo-Facorro[6,9], Rafael Romero-García[1,10,11].

Author affiliations:

[1]Department of Medical Physiology and Biophysics, University of Seville; Seville, Spain.

[2]Department of Psychology, University of Cambridge; Cambridge, UK.

[3]Department of Child and Adolescent Psychiatry and Behavioral Science, The Children's Hospital of Philadelphia; Philadelphia, PA, USA.

[4]Lifespan Brain Institute, The Children's Hospital of Philadelphia and Penn Medicine; Philadelphia, PA, USA.

[5]Translational Psychiatry Group, Seville Biomedical Research Institute (IBiS)-CSIC; Foundation for Health Research Management in Sevilla, Spain.

[6]Mental Health Service, Virgen del Rocío University Hospital; Seville, Spain. Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII; Seville, Spain.

[7]Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.

[8]Institute for Translational Medicine and Therapeutics, University of Pennsylvania, Philadelphia, PA, USA

[9]Department of Psychiatry. Marqués de Valdecilla University Hospital, IDIVAL, School of Medicine, University of Cantabria; Santander, Spain.

[10]Department of Psychiatry, University of Cambridge; Cambridge, UK.

[11]Instituto de Biomedicina de Sevilla (IBiS) HUVR/CSIC/University of Seville / CIBERSAM, ISCIII;

Seville, Spain.

Correspondence to: Rafael Romero García

Full address: Avda. Doctor Fedriani S/N, 41009, Seville (Spain)

Telephone: +34 954551768

E-mail: rr480@cam.ac.uk

Running title: Centiles and cognition in psychosis.

Keywords: Psychosis, normative modelling, centiles, cognition, longitudinal MRI, schizophrenia

ABSTRACT

Background: Clinical progression during psychosis has been closely associated with grey matter

abnormalities resulting from atypical brain development. However, the complex interplay

between psychopathology and neurodiversity challenges identifying neuroanatomical features

that anticipate long-term cognitive and symptomatic decline. Here, we collected MRI,

cognitive, and symptomatic data from 165 healthy controls and 357 drug-naïve or minimally

medicated FEP individuals that were followed up 1,3,5 and 10 years after the first episode.

(1778 MRI scans and assessments in total). Using normative modelling, we derived subject-

specific centile scores for cortical volume to investigate atypical deviations in FEP and their

relationship to long-term cognitive and symptomatic deterioration. The resulting centile

association maps were further characterized by examining their cytoarchitectural and

neurobiological attributes using normative atlases.

Aims: To investigate cortical volume longitudinal deviations in FEP using normative modelling,

exploring their relationship with long-term cognitive and symptomatic outcomes, as well as

their cytoarchitectural and neurobiological underpinnings.

Results: FEP centiles showed a widespread reduction at treatment initiation, with longitudinal

analysis showing an increase during treatment time, indicating convergence toward normal

maturation trajectories. Interestingly, this effect was reduced in highly medicated individuals.

Additionally, we found that cognitive impairments experienced during early FEP stages were

correlated with centiles and mitigated by time. Positive symptomatology was negatively

associated with regional centiles, and individuals with higher centiles benefited most from

treatment. Cytoarchitectural and neurobiological analyses revealed that regional centiles

related to FEP, as well as to cognitive function, were associated with specific molecular

features, such as regional serotonin receptor densities in heteromodal areas.

Conclusions: Collectively, these findings underscore the potential use of centile-based
normative modelling for a better understanding of how atypical cortical development
contributes to the long-term clinical progression of neurodevelopmental conditions.

INTRODUCTION

Atypical brain structure in FEP

First Episode Psychosis (FEP) is characterised by heterogeneous clinical presentations (1),
temporal progression (2,3), and responses to medication (4). Cross-sectional MRI studies
consistently report alterations in frontal and temporal cortices (5,6), with some identifying
changes in insular (7), parietal (8), and occipital regions (9). Longitudinal studies have
additionally revealed progressive cortical deterioration in FEP, especially in frontal and
temporal regions, over 1 (10), 2–3 (11,12), 5 (13), and 10 years (14). Despite these findings, the
complex interplay between brain development, sex, and neurodevelopmental pathophysiology
complicates the disentanglement of their individual contributions to brain structure and
function. Normative modelling addresses this by creating "growth charts" of brain
development (15), allowing individuals to be ranked and assigned centile scores based on
deviations from expected neurotypical trajectories. This approach has been used to identify
abnormal structural subtypes in autism (16) and deviations in ADHD symptoms (17). In
psychosis, normative modelling reveals deviations in cortical thickness in temporal areas during
high-risk states (18) and across the cortex in FEP (19), with these deviations diminishing during
treatment (20).

Brain structure and clinical outcomes

MRI studies have also extensively explored the clinical presentation of FEP, linking positive
symptoms, such as hallucinations and delusions, to thinning in frontal (21) and temporal (22)
cortices. Conversely, negative symptoms, like anhedonia and social withdrawal, are associated
with reduced orbitofrontal thickness (23). The effects of antipsychotics on brain structure
remain debated, with studies reporting both grey matter reductions (24) and increased
regional thickness (25). Cognitive decline in FEP has been observed prior to the onset of
psychosis (26,27), while post-onset trajectories vary, with reports of stabilization (28,29),
decline (30), or improvement (31). Normative modelling has shown neurocognitive delays in
youth reporting psychotic symptoms (32), but the long-term impact of antipsychotics on
cognition remains uncertain (33).

Regional vulnerability to atypical development

The spatial patterns of cortical deterioration shared across psychiatric and neurological conditions have been interpreted as a reflection of differential regional vulnerability to pathology (34). Under this hypothesis, cortical vulnerability to psychosis-related deterioration may reflect regional differences in cellular composition, neurotransmitter receptors, and metabolism (34,35), with regions of high serotonin and acetylcholine receptor density showing greater atypical deviations (36). In this study, we hypothesize that FEP patients exhibit atypical brain development influenced by treatment and medication, which impacts cognitive and symptom progression. We analysed baseline and 10-year follow-up longitudinal data to explore associations between brain deviations, clinical diagnosis, medication, cognition, and symptoms. Using cytoarchitectonic and neurobiological atlases, we additionally characterized psychosis-related brain deviations based on neurotransmitters, cell types, microstructure, and metabolism.

METODOLOGY

Subjects

MRI and phenotypic data were collected from healthy controls (n = 143; 76 males; mean age = 29.96 ± 7.45 years) and individuals with first-episode psychosis (FEP; n = 352; 214 males; mean age = 29.71 ± 8.77 years), who were followed longitudinally. Follow-up assessments were conducted at 1 (51 controls, 106 FEP), 3 (41 controls, 149 FEP), 5 (68 controls, 56 FEP), and 10 (94 controls, 118 FEP) years.

Recruitment was conducted through the Program for Attention to the Initial Phases of Psychoses (PAFIP) at Marqués de Valdecilla University Hospital and Valdecilla Health Research Institute (IDIVAL) in Spain. Ethics approval was granted by the CEIC-Cantabria (clinical trial numbers NCT0235832 and NCT02534363). Participants in the clinical group met DSM-IV criteria for schizophrenia spectrum disorders, including schizophrenia (n=169), schizophreniform disorder (n=102), schizoaffective disorder (n=6), brief psychotic disorder (n=49), and psychosis not otherwise specified (n=26). See a full list of inclusion and exclusion criteria in Supplementary Methods. Detailed demographic and clinical information stratified by sex and diagnosis are provided in Supplemental Material (Figs. S1-S2 and Tables S1-S4).

Cognitive and symptom assessment

Cognition was assessed for the following domains: (1) verbal memory: Rey Auditory Verbal Learning Test (RAVLT) long-term recall score; (2) visual memory: Rey Complex Figure test (RCFT) long-term recall score; (3) motor dexterity: grooved pegboard (GP), time to complete with dominant hand; (4) executive functions: Trail Making Test part B (TMTb); (5) working memory: WAIS III-Backward Digits (BD) total score; (6) speed of processing: WAIS III-Digit Symbol (DS) standard total score; (7) attention: Continuous Performance Test Degraded-Stimulus (CPT-DS), the total number of correct responses (37). For each cognitive test, z-scores were computed by subtracting the mean and dividing by the standard deviation of the control group's scores. Overall cognitive functioning was calculated as the mean z-score across the seven cognitive tests for each individual. FEP participants were also assessed using the Scale for the Assessment of Negative Symptoms (SANS, 21 items), Scale for the Assessment of Positive Symptoms (SAPS, 30 items), and Brief Psychiatric Rating Scale (BPRS, 24 items).

Principal Component Analysis (PCA) was conducted on cognition and symptom items to compare with average scores used in the calculations. Sensitivity analyses examined (i) the impact of cannabis use and (ii) study dropout on cognitive and symptom measures. Psychological evaluations were performed by experienced psychiatrists using the structured clinical interview for DSM-IV, with diagnoses confirmed at 6 months.

MRI acquisition and volume extraction

Structural MRI scans were acquired using a 1.5T General Electric SIGMA System (GE, Milwaukee, USA) and a 3T Philips Medical Systems MRI scanner (Achieva, Best, The Netherlands) equipped with an 8-channel head coil. Baseline and follow-up scans for each individual were consistently conducted using the same machine. The imaging protocol included a T1-weighted image that underwent visual inspection for QC. The parameters for 1.5T were: TE=5ms, TR=24ms, NEX=2, rotation angle=45°, FOV=26×19.5cm, slice thickness=1.5mm, voxel size=1.02x1.02x1.5 mm, and a matrix of 256×192, whereas for 3T were TE = 3.7ms, TR=8.2ms, flip angle=8°, acquisition matrix=256×256, voxel size=0.94x0.94x1 mm and 160 contiguous slices. Regional volumes were computed with FreeSurfer 6.0.0's recon-all for each region defined in the Desikan-Killiany cortical parcellation (34 regions per hemisphere). Outliers (>5 SD from the mean) were excluded. Subjects were distributed across scanners as follows: GE 1.5T (28.3% FEP, 12.5% controls) and Philips 3T (39.8% FEP, 19.5% controls).

Regional volumetric centile estimation

Normative trajectories of lifespan grey matter volume (15) were used to benchmark cortical volumes from the Desikan-Killiany atlas against data from more than 100,000 neurotypical individuals (https://github.com/brainchart/Lifespan). Because these trajectories were based on hemispheric-averaged regional volumes, the same approach was applied to our dataset. Age-normed, sex-stratified, and site-corrected deviations were derived and expressed as centile scores. Centile scores indicate the relative position of an individual's grey matter volume compared with normative lifespan expectations. Values below 0.5 reflect lower-than-expected volumes, whereas values above 0.5 reflect preserved or increased volumes. Residual effects of site or motion (Euler index) on centile scores were assessed using ANOVA.

Baseline analyses using multivariate regression

To evaluate the impact of FEP diagnosis on baseline centiles, a multivariate regression was performed for each cortical region using the following model:

$$regional\ centile \sim 1 + diagnosis + sex + age\ of\ inclusion + etiv \quad (1)$$

where "diagnosis" was a binary variable (control vs. FEP), "age of inclusion" referred to participants' age at the first scan, and "etiv" represented cranial volume residuals after age and sex correction. "Age of inclusion" and "etiv" were Z-scored prior to regression. Statistical analyses were performed on 143 controls and 352 FEP subjects, with multiple comparisons corrected using False Discovery Rate (FDR).

Longitudinal analyses using Mixed Modelling

The longitudinal effects of disease and medication on centiles and clinical outcomes were analysed using Mixed Modelling over 1,178 assessments (397 controls, 781 FEP). Antipsychotic medication exposure was quantified as chlorpromazine equivalents at the time of the assessment (CPZ-equivalents) (38).

Linear Mixed Modelling for predicting regional centiles as a function of disease progression and treatment

The impact of time from the first scan (for controls) and time from treatment initiation (for FEP), collectively referred to as time, in regional centiles were assessed using Linear Mixed Modelling (LMM):

$$regional\ centile \sim 1 + diagnosis + sex + age\ at\ inclusion + etiv + medication$$
$$+ time{:}diagnosis + medication{:}time + (1|subject) \quad (2)$$

where, in addition to the aforementioned variables, we also considered: medication at the

time of MRI acquisition (antipsychotic dose in CPZ-equivalents), time:diagnosis (interaction

between time and diagnosis) and medication:time (interaction indicating whether medication

alters the effect of treatment time on centiles) and "1|subject" as a random intercept to

account for random subject-specific offsets overall. In this model, the interaction between time

and diagnosis captures group-specific trajectories, allowing FEP and Control subjects to exhibit

distinct slopes over time. "Age of inclusion", "etiv", "Medication" and "time" were Z-scored

prior to regression.

Sensitivity analyses repeated these models using raw regional volumes instead of centiles as

the dependent variable.

LMM for predicting cognitive functioning as a function of treatment and regional centiles

192   After exploring the effect of disease and treatment on centiles, we evaluated how these factors

193   mediate overall cognitive functioning:

$$\begin{aligned} cognition \sim 1 + \; & diagnosis + \; sex \; + \; age\;at\;inclusion \; + \; etiv + \; medication \\ & + \; time{:}diagnosis \;\; + \; medication{:}time + centile{:}diagnosis \\ & + centile{:}time + (1|\;subject) \quad\quad (3) \end{aligned}$$

194   where, in this case, regional centile is considered as an independent variable. Through

195   diagnosis interaction variables, we assessed the differential impact of time and centiles on the

196   control and FEP groups using a single model.

Generalized Mixed Modelling for predicting clinical symptomatology as a function of treatment and regional centiles

199   Symptomatology (BPRS, SAPS, and SANS scores) was modelled as:

$$\begin{aligned} symptoms \sim 1 + \; & sex \; + age\;at\;inclusion \; + \; etiv + centile + time + \; medication \\ & + medication{:}time + centile{:}medication + centile{:}time \\ & + \; (1|\;subject) \quad (4) \end{aligned}$$

200   Generalized Mixed Models with a Poisson distribution were used due to the count-like nature

201   of symptom scores and their alignment with exponential decay patterns. Separate analyses

202   were conducted for each psychometric scale.

Cytoarchitectural characterization of centile associations

Cortical centiles associated with phenotypic variables (diagnosis, medication, cognition, BPRS, SAPS, SANS) were mapped onto the cortical hierarchies defined by Mesulam atlas (unimodal, paralimbic, idiotypic, heteromodal, https://github.com/ucam-department-of-psychiatry/maps_and_parcs, Supplementary **Table S5,** (39)). ANOVA tests and Tukey post-hoc analyses were used to identify differential distributions of centile associations across Mesulam areas.

Neurobiological mapping of centile associations

Centile-phenotypic associations were also profiled using 46 molecular and microarchitectural maps derived from MRI/PET studies, expanding on the methodology presented on (40) and implemented at https://github.com/netneurolab/neuromaps and https://github.com/RafaelRomeroGarcia/NeurobiologyCentilesPsychosis. These maps included: neurotransmitter receptors (5-HT$_{1A}$, 5-HT$_{1B}$, 5-HT$_{2A}$, 5-HT$_4$, 5-HTT, H$_3$, D$_1$, D$_2$, DAT, NET, $\alpha_4\beta_2$, VAChT, CB$_1$, M$_1$, MOR, mGluR$_5$, NMDA, GABA), cell types (astrocytes, endothelial cells, microglia, oligodendrocytes, oligodendrocytes precursors, excitatory neurons, inhibitory neurons), cortical layers (I-VI), microstructural properties (synapse density, neurotransmitter PC1, gene expression PC1 [which is highly driven by cell types (41)], cortical thickness, myelin), metabolism (glycolytic index, cerebral blood flow, cerebral blood volume, oxygen metabolism and glucose metabolism), cortical expansion (evolutionary expansion, developmental expansion, allometric scaling from Philadelphia Neurodevelopmental Cohort, allometric scaling from National Institutes of Health). See supplementary **Table S6** for the full list of neurobiological features included in the analysis.

Principal Component – Canonical Correlation Analysis (PC-CCA; https://github.com/RafaelRomeroGarcia/cca_pls_toolkit) was used to identify combinations of neurobiological features that best explained centile-phenotypic associations (42). PC-CCA reduces data dimensionality using PCA to minimize overfitting and then identifies the linear combination (weighted sum of loadings) of the neurobiological maps that best predicts the inter-regional variance of each centiles-phenotypic association map. Statistical significance was evaluated using spatial autocorrelation-preserving permutation tests (spin tests; https://github.com/frantisekvasa/rotate_parcellation (43)) with 10,000 parcellation-specific rotations. To validate the multivariate patterns identified with PC-CCA, we conducted a sensitivity analysis with Partial Least Squares (PLS). PLS maximizes the covariance between the two variable sets, providing a robust alternative when collinearity might affect the canonical solution (42).

RESULTS

Impact of diagnosis and treatment on centiles

Using multivariate linear regression on baseline data, FEP patients demonstrated significantly lower total grey matter volume centiles compared to controls (t = -2.64, p = 0.0085), but no reductions in total white matter centiles (t = -0.04, p = 0.97; **Table S7**). Consistently, regional analyses showed widespread cortical reductions in centiles associated with diagnosis (**Fig. 1**, Baseline). Covariates such as age at inclusion and etiv correlated positively with centiles, while females exhibited lower centiles (**Fig. 1**, Baseline). Effect sizes and FDR-corrected significance levels are fully provided in the supplementary data. Centiles were not significantly associated with motion artifacts quantified using the Euler index (Spearman's rho = -0.016, p = 0.587; **Fig. S3**).

Longitudinal analyses using LMM over 10 years revealed that longer treatment duration in FEP patients was associated with increased global centile scores, progressively approaching normative values (t = 5.3, p < 10^{-6}; **Table S8**), whereas controls showed no time-dependent association (t = -0.3, p = 0.75). Regionally, significant diagnosis-centile associations were observed in the pars orbitalis, superior temporal, transverse temporal, and lateral occipital areas (**Fig. 1**, Longitudinal). Medication (CPZ-equivalent) was negatively associated with centiles in temporal and frontal regions. Centiles increased with time in FEP but not in control (see **Fig. S4A** for an illustration of this interaction), however, this was attenuated in individuals with higher medication doses.

These LMM analyses were repeated using raw volumes instead of centiles. As shown in **Fig. S5**, age-related reductions of regional volume dominated all interaction effects, masking the separate trajectories in controls and FEP described by the centile approach.

Fig. 1. Associations between phenotypic data and covariates with regional centiles. **Top panel.**
Contribution of each variable to the multivariate regression of baseline data. **Bottom panel**
Contribution of each variable to the LMM of longitudinal changes in centiles (up to 10 years
follow-up). Scale represents t-values associated with each regression parameter. Non-
significant contributions (P_{fdr} ≥0.05) are depicted with desaturated colours.

Regional centiles associated with cognitive impairment

Principal component analysis (PCA) of cognitive subscales revealed a first PC explaining 45.3%
of the variance, with similar weights across the seven subscales (Table S9), so for simplicity, the
mean score was used in subsequent analyses. Cognitive function was negatively associated
with FEP diagnosis (**Fig. 2**, diagnosis) and correlated extensively with regional centiles in FEP,
but not in controls, indicating that cognitive impairment is linked to atypical volume
development in psychosis (**Fig. 2**, centile - diagnosis interaction). This differential association is

illustrated for a representative region in **Fig. S4B**. Time positively influenced cognitive function

in FEP but not in controls. Negative interaction between medication and time indicates that

cognitive improvement is reduced in highly medicated patients (illustrated in **Fig. S24C**). Other

covariates showed either a negative (age of inclusion) or no association (sex, etiv, medication,

centile-time interaction) with cognition.

Fig. 2. Associations between phenotypic data, covariates and centiles with cognitive

performance. Contribution of each variable to the LMM of longitudinal changes in cognition

(up to 10 years follow-up). Scale represents t-values associated with each regression

parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated.

Regional centiles associated with symptomatology

Treatment time correlated negatively with BPRS, SAPS, and SANS scores, suggesting symptom reduction over time (**Fig. 3**). Medication was associated with reductions in BPRS and SAPS scores but increased SANS scores, likely due to pharmacological specificity for positive symptoms. A positive medication-time interaction indicates that symptom improvement with time were less pronounced in highly medicated patients. Positive symptoms (SAPS) were negatively associated with centiles, particularly overlapping with BPRS, whereas SANS showed no centile correlation. Younger age at onset was linked to more severe positive symptoms (SAPS).

No significant differences were observed in cognitive or symptom scores between cannabis users and non-users (**Table S10**) or between participants who completed the study and those who dropped out (**Table S11**).

Fig. 3. Associations between phenotypic data, covariates and centiles with symptomatology. Contribution of each variable to the GMM of longitudinal changes in BPRS, SAPS and SANS (each column represent different models). Scale represents the Wald z-statistic associated with each regression parameter. Non-significant contributions ($P_{fdr} \geq 0.05$) are depicted with desaturated colours.

Cytoarchitectural and neurobiological characterization of FEP-related regional centiles

Using the Mesulam cytoarchitectonic atlas (39), we characterized regional associations between centiles, treatment, cognition, and symptoms. Centiles related to cognitive function in FEP were predominantly located in unimodal, paralimbic, and heteromodal cortices, compared to idiotypic cortex (**Fig. 4A**). Conversely, the association between centiles and BPRS and SANS was more negative in heteromodal areas than in paralimbic. Finally, the correlation between centiles and SAPS scale was significantly more negative in paralimbic cortex than in unimodal cortex (all ANOVA, Post-hoc Tukey, P_{fdr} <0.05). No preferential location was identified for centiles associated with cognitive function in control participants.

PCA-CCA was used to capture associations between neurobiological data from normative individuals (40) and centiles related to clinical outcomes. Neurobiological mapping revealed that regions associated with FEP diagnosis (Fig. 1) co-located with areas rich in neurotransmitters such as 5-HT$_{1B}$, 5-HT$_{2A}$, M$_1$, and NMDA, as well as neurons and metabolic features (**Fig. 4B**, negative loadings). Conversely, FEP diagnosis-related regions were associated with lower glial cell densities and 5-HT$_{1A}$ neurotransmitter levels (positive loadings). Similarly, regions negatively impacted by medication were linked to high concentrations of 5-HT$_{1A}$, 5-HT$_4$, CB$_1$, D$_2$, NET, and glial cells, as well as layers I, II, III, and VI thickness.

Centiles associated with cognitive function in FEP were co-located in areas rich in 5-HT$_{2A}$, 5-HT$_4$, $\alpha_4\beta_2$, CB1, MOR, and NET, as well as synapse density and metabolic markers such as CBF, CBV, and CMRGlu (**Fig. 4C**). Control participant analyses revealed no significant co-locations, suggesting specificity to FEP. Neurobiological associations with symptoms showed similarities for BPRS and SANS (SAPS model was not significant), with neurotransmitter correlations (positive for 5-HT$_{1A}$, 5-HTT, and D$_2$; negative for 5-HT$_{1B}$, 5-HT$_{2A}$, NMDA) and cellular features (positive for glia, negative for neurons). They also show differences in $\alpha_4\beta_2$, GABA, M1 and CMRGlu (for BPRS) and in NET receptors and thickness of layer III (for SANS).

Collectively, these results reveal a significant co-location of atypical brain maturation in FEP with specific neurobiological factors, suggesting that they may play an important role in shaping the structural vulnerability to FEP symptomatology. Consistency analyses using PLS instead of PCA-CCA yielded highly similar neurobiological loading estimates (all r-values > 0.98; **Fig. S6**).

Fig. 4. Cytoarchitectural and neurobiological characterisation of FEP-related centiles. **A)** Distribution of t-values shown in Figs. 2 and 3 across the four cortices delineated in the atlas of Mesulam. Each dot represents a brain region in the Desikan-Killiany atlas. **B)** Neurobiological maps co-located with the diagnosis-centile and medication-centile associations. Positive loadings indicate neurobiological features that are co-located with regions where centiles were positively associated with the variables of interest (in this case, diagnosis and medication). Conversely, negative loadings indicate co-location with regions negatively associated with the variable of interest. **C)** Neurobiological maps co-located with the association between centiles

341 and clinical outcomes (cognitive function, BPRS SAPS, and SANS). "N.S." denotes non-significant

342 models ($P_{fdr} \geq 0.05$). For significant models, only significant ($P_{fdr} < 0.05$) loadings are displayed.

DISCUSSION

In this study, we examined cortical volume deviations using normative centiles models in both

neurotypical and FEP participants scanned over the course of 10 years. Our findings indicated

that FEP participants had lower regional centiles than controls in multiple cortical areas, a

difference that decreased in intensity over the treatment period. However, this convergence

between patients and controls was less pronounced in those who were highly medicated.

Cognitive functioning in FEP was positively correlated with centiles co-located with regions

with high serotonin receptor densities. These results highlight the value of normative

approaches for better understanding the long-term relationship between cortical maturation

and clinical profiles in psychosis.

Our normative analysis revealed atypical developmental values in FEP patients who exhibited a

generalised reduction in regional cortical volume centile scores (19). Previous studies have

extensively reported reductions in cortical volume and thickness at different stages of

psychosis-related conditions (7,9,19,44). As shown by the ENIGMA consortium, although

frontal and temporal cortices are the regions showing the strongest effect sizes when

compared to normative controls, schizophrenia is also characterised by a generalised reduction

over the whole cortex (45). Nevertheless, a major challenge in traditional case-control studies

is the lack of personalised metrics capable of detecting individuals with atypical

neurodevelopment. Conversely, normative modelling leverages data from thousands of

individuals for identifying participants with abnormal trajectories. Using this approach, Worker

et al. 2023 (19), demonstrated that a large and widespread number of extreme negative

deviations in cortical thickness centiles among FEP exist, revealing that this condition is

characterised not only by a diminished group-average cortical thickness but also by specific

individuals that exhibit severe thickness reductions.

The combination of normative modelling with long-term longitudinal MRI revealed that

centiles increased during the treatment period of FEP participants. These findings suggest that

grey matter reductions are more severe during the early stages of psychosis (46), and the

differences between the FEP and control groups decrease over time (25,47,48) . Berthet et al.

(2025) (20) also reported this trend toward a reduced difference over time between controls

and FEP patients when investigating cortical thickness using normative modelling. Since this

study did not include untreated patients, we cannot disentangle the specific effects of

treatment from the natural progression of the disease.

The progressive convergence of centiles to the expected normative values during treatment

might suggest that the drugs elicit neuroplasticity in FEP patients, however, potential late

effects of neurodegenerative pathogenesis cannot be discarded (49). Importantly, as most

participants were prescribed with antipsychotic drugs, we cannot fully untangle the causal role

of medication in cortical volume reductions. Medication has been previously associated with

grey matter loss (50), specifically attributed to caspase-3-mediated neurotoxicity (51,52). In

this line, we also found that individuals on high medication doses did not show a generalized

cortical reduction effect, but rather exhibited localized reductions in the temporal and frontal

areas. As suggested by Fusar-Poli et al. 2013 metanalysis (53), long-term GM reductions may be

the consequence of the cumulative exposure to the antipsychotics, a finding also supported by

other studies (24,54).

While describing the anatomical alterations related to the progression and treatment of

psychosis is of great interest, understanding how these changes impact patients' cognitive

functionality is of crucial clinical importance. We reported reduced cognitive abilities in drug-

naïve and minimally medicated FEP participants immediately after the onset, suggesting that

impairment occurs even before the first episode (26,55,56). Cognitive functionality also

improved throughout the treatment period, indicating that while medication targets positive

symptoms, it may also lead to cognitive improvement, albeit as an indirect effect. (26).

Previous studies have also demonstrated cognitive improvement in patients after one (11) or

three (57) years of antipsychotic treatment. Nevertheless, our LMM additionally found that

medication played a mediating role in the association between treatment duration and

cognitive function, leading to an attenuation of cognitive recovery over time for patients with

higher medication doses. In line with this observation, Kawai et al. 2006 (58) demonstrated

that dose-reductions lead to improvements in cognitive performance in a limited sample of

individuals treated with multiple conventional antipsychotics. In addition to treatment

duration, the other factor showing a positive relation with cognitive function was regional

centiles which aligns with the associations between cognition and structural features such

volume and thickness described in previous non-normative FEP studies (8,59–62).

Similar to cognitive progression, treatment yielded a positive effect on FEP-related

symptomatology. As expected, both time and medication primarily had an impact on positive

symptoms. Conversely, time had a positive but weaker effect on the reduction of negative

symptoms. Despite the fact that medication, especially first-generation antipsychotics, does

not alleviate negative symptoms, meta-analyses of placebo-control trials have indeed revealed

that most treatments can help reduce negative symptomatology (63). Nevertheless, here, we

observed opposite trends in the model slopes of time (negative) and medication (positive) with

SANS, indicating that heavily medicated individuals do not experience negative symptoms

improvements over time. This may reflect the diverse and distinct recovery trajectories of

illness, with a significant proportion of patients experiencing relapse and showing no

improvement in negative symptoms (64). FEP symptomatology was also associated with

regional volumes, with higher centiles values generally associated with lower positive

symptoms. Similarly, previous studies have associated positive symptoms with cortical

alterations in prefontal, temporal and parietal areas (22). Conversely, negative symptoms

exhibited no correlation with centiles, suggesting that while treatment and medication may

provide moderate improvement in this domain, these symptoms remain relatively stable and

do not significantly influence cortical plasticity. However, further placebo-controlled trials will

be necessary to elucidate this (64).

Centiles related with different aspects of FEP were co-located with regions with specific

microarchitectural and neurobiological features. Microarchitecturally, cognitive functioning was

associated with centiles preferentially located in association (heteromodal, unimodal) and

paralimbic cortices rather than idiotypic (primary) regions. Extensive literature has highlighted

the crucial role of heteromodal and paralimbic regions in higher-order cognitive functioning,

specifically linking these regions to cognitive decline in psychosis (65–67). Neurobiologically,

serotonin neurotransmitters were predominantly present in regions associated with psychosis

diagnosis, medication and cognitive functioning. This may be related with the role of this

neurotransmitter mediating the effect of antipsychotic medication which affects mood and

cognitive function (68). We also reported differences in centile associations across receptor

subtypes such as $5HT_{1A}$ and $5HT_{2A}$ which could be a reflection of its complex role in psychosis

(69,70). Additionally, the high density of dopamine receptors in regions associated with

medication suggests a potential pathway whereby elevated levels of antipsychotic medications

disproportionately affect dopaminergic regions. Moreover, diagnosis and symptom-related

centiles were not only associated with neuronal density maps but also with glial cells,

indicating a potential involvement of immunological and inflammatory risk factors (71–73).

Limitations

Several limitations must be acknowledged. Firstly, the primary inclusion criterion was the

diagnosis of FEP at baseline, regardless of subsequent follow-up diagnoses, which

predominantly included schizophrenia but also other psychotic disorders. Secondly, medication

was standardized as chlorpromazine equivalents to simplify analysis and reduce model

overfitting. However, this approach fails to capture the specific effects of different medications.

Finally, higher medication doses were generally prescribed to individuals with more resistant

positive symptoms. However, these prescriptions were influenced by factors such as age of

onset and treatment duration, complicating the disentanglement of individual contributions in

the models.

Conclusions

This study applied a normative modelling approach to demonstrate that FEP is associated with

regional decreases in cortical centiles, with partial reversal over time in low-medicated

individuals. Improvements in cognitive abilities and symptomatology were positively associated

with time. Additionally, individuals with centiles closer to normative values exhibited better

cognitive performance and less severe positive symptoms. Regions sensitive to cognitive

function and symptomatology co-located with higher serotonin receptor densities and other

neurobiological features. Collectively, these findings provide critical insights into the long-term

interactions between cortical structure, treatment, medication, cognitive function, and

symptom profiles.

Data and Code availability

All code and non-clinical data used to perform the analyses can be found at

https://github.com/RafaelRomeroGarcia/LongitudinalCentilesFEP/. Data from patients is

available upon request in accordance with ethical regulations. All statistical results are provided

in a supplementary Excel file.

Acknowledgements

We thank Agoston Mihalik, Golia Shafiei, Bratislav Misic, Victor Ortiz and Lifespan Brain Chart

Consortium for their contribution.

Funding

RRG is funded by the EMERGIA Junta de Andalucía program (EMERGIA20_00139), the *Plan*

Propio of the University of Seville and the Plan de Consolidación (CNS2023-143647). Both RRG

and CAM, are funded by the *Plan de Generación de Conocimiento* from the Agencia Estatal de

Investigación (PID2021-122853OA-I00).

Competing interests

RAIB and JS hold equity in and are directors of Centile Bioscience. All other authors declare that

they have no known competing interests.

REFERENCES

1. Voineskos AN, Jacobs GR, Ameis SH. Neuroimaging Heterogeneity in Psychosis:
Neurobiological Underpinnings and Opportunities for Prognostic and Therapeutic
Innovation. Biological Psychiatry. 1 de julio de 2020;88(1):95-102.

2. Prakash J, Chatterjee K, Srivastava K, Chauhan VS. First-episode psychosis: How long
does it last? A review of evolution and trajectory. Ind Psychiatry J. 2021;30(2):198-206.

3. Gaebel W, Zielasek J. Focus on psychosis. Dialogues Clin Neurosci. marzo de
2015;17(1):9-18.

4. Leucht S, Crippa A, Siafis S, Patel MX, Orsini N, Davis JM. Dose-Response Meta-
Analysis of Antipsychotic Drugs for Acute Schizophrenia. AJP. abril de 2020;177(4):342-
53.

5. Pantelis C, Velakoulis D, McGorry PD, Wood SJ, Suckling J, Phillips LJ, et al.
Neuroanatomical abnormalities before and after onset of psychosis: a cross-sectional and
longitudinal MRI comparison. Lancet. 25 de enero de 2003;361(9354):281-8.

6. Oertel-Knöchel V, Knöchel C, Rotarska-Jagiela A, Reinke B, Prvulovic D, Haenschel C,
et al. Association between Psychotic Symptoms and Cortical Thickness Reduction across
the Schizophrenia Spectrum. Cerebral Cortex. 1 de enero de 2013;23(1):61-70.

7. Crespo-Facorro B. Insular cortex abnormalities in schizophrenia: a structural magnetic
resonance imaging study of first-episode patients. Schizophrenia Research. 30 de
noviembre de 2000;46(1):35-43.

8. Yildiz M, Borgwardt SJ, Berger GE. Parietal Lobes in Schizophrenia: Do They Matter?
Schizophr Res Treatment. 2011;2011:581686.

9. Tordesillas-Gutierrez D, Ayesa-Arriola R, Delgado-Alvarado M, Robinson JL, Lopez-
Morinigo J, Pujol J, et al. The right occipital lobe and poor insight in first-episode
psychosis. PLoS One. 2018;13(6):e0197715.

10. Del Re EC, Stone WS, Bouix S, Seitz J, Zeng V, Guliano A, et al. Baseline Cortical
Thickness Reductions in Clinical High Risk for Psychosis: Brain Regions Associated with
Conversion to Psychosis Versus Non-Conversion as Assessed at One-Year Follow-Up in
the Shanghai-At-Risk-for-Psychosis (SHARP) Study. Schizophr Bull. 16 de marzo de
2021;47(2):562-74.

11. Zipparo L, Whitford TJ, Redoblado Hodge MA, Lucas S, Farrow TFD, Brennan J, et al.
Investigating the neuropsychological and neuroanatomical changes that occur over the first
2-3 years of illness in patients with first-episode schizophrenia. Prog
Neuropsychopharmacol Biol Psychiatry. 15 de febrero de 2008;32(2):531-8.

12. Cobia DJ, Smith MJ, Wang L, Csernansky JG. Longitudinal progression of frontal and
temporal lobe changes in schizophrenia. Schizophrenia Research. 1 de agosto de
2012;139(1):1-6.

13. van Haren NEM, Hulshoff Pol HE, Schnack HG, Cahn W, Mandl RCW, Collins DL, et al.
Focal gray matter changes in schizophrenia across the course of the illness: a 5-year follow-
up study. Neuropsychopharmacology. octubre de 2007;32(10):2057-66.

14. Rodriguez-Perez N, Ayesa-Arriola R, Ortiz-García de la Foz V, Setien-Suero E,
Tordesillas-Gutierrez D, Crespo-Facorro B. Long term cortical thickness changes after a
first episode of non- affective psychosis: The 10 year follow-up of the PAFIP cohort.
Progress in Neuro-Psychopharmacology and Biological Psychiatry. 8 de junio de
2021;108:110180.

15. Bethlehem RAI, Seidlitz J, White SR, Vogel JW, Anderson KM, Adamson C, et al. Brain
charts for the human lifespan. Nature. 21 de abril de 2022;604(7906):525-33.

16. Shan X, Uddin LQ, Xiao J, He C, Ling Z, Li L, et al. Mapping the Heterogeneous Brain
Structural Phenotype of Autism Spectrum Disorder Using the Normative Model. Biological
Psychiatry. 1 de junio de 2022;91(11):967-76.

17. Marquand AF, Rezek I, Buitelaar J, Beckmann CF. Understanding Heterogeneity in
Clinical Cohorts Using Normative Models: Beyond Case-Control Studies. Biological
Psychiatry. 1 de octubre de 2016;80(7):552-61.

18. ENIGMA Clinical High Risk for Psychosis Working Group. Normative Modeling of Brain
Morphometry in Clinical High Risk for Psychosis. JAMA Psychiatry. 1 de enero de
2024;81(1):77-88.

19. Worker A, Berthert P, Lawrence AJ, Kia SM, Arango C, Dinga R, et al. Extreme deviations
from the normative model reveal cortical heterogeneity and associations with negative
symptom severity in first-episode psychosis from the OPTiMiSE and GAP studies. Transl
Psychiatry. 2 de diciembre de 2023;13(1):1-9.

20. Berthet P, Haatveit BC, Kjelkenes R, Worker A, Kia SM, Wolfers T, et al. A 10-Year
Longitudinal Study of Brain Cortical Thickness in People with First-Episode Psychosis
Using Normative Models. Schizophrenia Bulletin. 20 de diciembre de 2024;51(1):95-107.

21. Padmanabhan JL, Tandon N, Haller CS, Mathew IT, Eack SM, Clementz BA, et al.
Correlations Between Brain Structure and Symptom Dimensions of Psychosis in
Schizophrenia, Schizoaffective, and Psychotic Bipolar I Disorders. Schizophrenia Bulletin.
1 de enero de 2015;41(1):154-62.

22. Walton E, Hibar DP, van Erp TG, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, et al.
Positive symptoms associate with cortical thinning in the superior temporal gyrus via the
ENIGMA-Schizophrenia consortium. Acta Psychiatr Scand. mayo de 2017;135(5):439-47.

23. Walton E, Hibar DP, van Erp TGM, Potkin SG, Roiz-Santiañez R, Crespo-Facorro B, et al.
Prefrontal cortical thinning links to negative symptoms in schizophrenia via the ENIGMA
consortium. Psychol Med. enero de 2018;48(1):82-94.

24. Vita A, De Peri L, Deste G, Barlati S, Sacchetti E. The Effect of Antipsychotic Treatment
on Cortical Gray Matter Changes in Schizophrenia: Does the Class Matter? A Meta-
analysis and Meta-regression of Longitudinal Magnetic Resonance Imaging Studies. Biol
Psychiatry. 15 de septiembre de 2015;78(6):403-12.

25. Goghari VM, Smith GN, Honer WG, Kopala LC, Thornton AE, Su W, et al. Effects of
eight weeks of atypical antipsychotic treatment on middle frontal thickness in drug-naïve
first-episode psychosis patients. Schizophrenia Research. 1 de septiembre de
2013;149(1):149-55.

26. Bora E, Murray RM. Meta-analysis of cognitive deficits in ultra-high risk to psychosis and
first-episode psychosis: do the cognitive deficits progress over, or after, the onset of
psychosis? Schizophr Bull. julio de 2014;40(4):744-55.

27. Lecardeur L, Meunier-Cussac S, Dollfus S. [Cognitive deficits in first episode psychosis
patients and people at risk for psychosis: from diagnosis to treatment]. Encephale. mayo de
2013;39 Suppl 1:S64-71.

28. Rund BR, Barder HE, Evensen J, Haahr U, Hegelstad W ten V, Joa I, et al. Neurocognition
and Duration of Psychosis: A 10-year Follow-up of First-Episode Patients. Schizophr Bull.
enero de 2016;42(1):87-95.

29. McCleery A, Nuechterlein KH. Cognitive impairment in psychotic illness: prevalence,
profile of impairment, developmental course, and treatment considerations. Dialogues Clin
Neurosci. septiembre de 2019;21(3):239-48.

30. Fett AKJ, Velthorst E, Reichenberg A, Ruggero CJ, Callahan JL, Fochtmann LJ, et al.
Long-term Changes in Cognitive Functioning in Individuals With Psychotic Disorders:
Findings From the Suffolk County Mental Health Project. JAMA Psychiatry. 1 de abril de
2020;77(4):387-96.

31. Burgher B, Scott J, Cocchi L, Breakspear M. Longitudinal changes in neural gain and its
relationship to cognitive control trajectory in young adults with early psychosis. Transl
Psychiatry. 3 de marzo de 2023;13(1):1-9.

32. Gur RC, Calkins ME, Satterthwaite TD, Ruparel K, Bilker WB, Moore TM, et al.
Neurocognitive Growth Charting in Psychosis Spectrum Youths. JAMA Psychiatry. 1 de
abril de 2014;71(4):366-74.

33. Husa AP, Moilanen J, Murray GK, Marttila R, Haapea M, Rannikko I, et al. Lifetime
antipsychotic medication and cognitive performance in schizophrenia at age 43 years in a
general population birth cohort. Psychiatry Res. enero de 2017;247:130-8.

34. Hettwer MD, Larivière S, Park BY, van den Heuvel OA, Schmaal L, Andreassen OA, et al.
Coordinated cortical thickness alterations across six neurodevelopmental and psychiatric
disorders. Nat Commun. 11 de noviembre de 2022;13(1):6851.

35. Hansen JY, Shafiei G, Vogel JW, Smart K, Bearden CE, Hoogman M, et al. Local
molecular and global connectomic contributions to cross-disorder cortical abnormalities.
Nature Communications. 10 de agosto de 2022;13(1):4682.

36. García-San-Martín N, Bethlehem RA, Mihalik A, Seidlitz J, Sebenius I, Alemán-Morrillo
C, et al. Molecular and micro-architectural mapping of abnormal gray matter developmental
trajectories in psychosis [Internet]. medRxiv; 2023 [citado 14 de mayo de 2024]. p.
2023.12.11.23299652. Disponible en:
https://www.medrxiv.org/content/10.1101/2023.12.11.23299652v1

37. Rodríguez-Sánchez JM, Setién-Suero E, Suárez-Pinilla P, Son JMV, Vázquez-Bourgon J,
López PG, et al. Ten-year course of cognition in first-episode non-affective psychosis
patients: PAFIP cohort. Psychological Medicine. marzo de 2022;52(4):770-9.

38. Danivas V, Venkatasubramanian G. Current perspectives on chlorpromazine equivalents:
Comparing apples and oranges! Indian J Psychiatry. 2013;55(2):207-8.

39. Mesulam MM, Mesulam MM, editores. Principles of behavioral and cognitive neurology.
2. ed. Oxford: Oxford Univ. Press; 2000. 540 p.

40. Hansen JY, Shafiei G, Markello RD, Smart K, Cox SML, Nørgaard M, et al. Mapping
neurotransmitter systems to the structural and functional organization of the human
neocortex. Nat Neurosci. noviembre de 2022;25(11):1569-81.

41. Dear R, Wagstyl K, Seidlitz J, Markello RD, Arnatkevičiūtė A, Anderson KM, et al.
Cortical gene expression architecture links healthy neurodevelopment to the imaging,
transcriptomics and genetics of autism and schizophrenia. Nat Neurosci. junio de
2024;27(6):1075-86.

42. Mihalik A, Chapman J, Adams RA, Winter NR, Ferreira FS, Shawe-Taylor J, et al.
Canonical Correlation Analysis and Partial Least Squares for Identifying Brain-Behavior
Associations: A Tutorial and a Comparative Study. Biol Psychiatry Cogn Neurosci
Neuroimaging. noviembre de 2022;7(11):1055-67.

43. Váša F, Seidlitz J, Romero-Garcia R, Whitaker KJ, Rosenthal G, Vértes PE, et al.
Adolescent Tuning of Association Cortex in Human Structural Brain Networks. Cereb
Cortex. 1 de enero de 2018;28(1):281-94.

44. Gallardo-Ruiz R, Crespo-Facorro B, Setién-Suero E, Tordesillas-Gutierrez D. Long-Term
Grey Matter Changes in First Episode Psychosis: A Systematic Review. Psychiatry
Investig. mayo de 2019;16(5):336-45.

45. Thompson PM, Jahanshad N, Ching CRK, Salminen LE, Thomopoulos SI, Bright J, et al.
ENIGMA and global neuroscience: A decade of large-scale studies of the brain in health
and disease across more than 40 countries. Transl Psychiatry. 20 de marzo de
2020;10(1):100.

46. Pantelis C, Yücel M, Wood SJ, Velakoulis D, Sun D, Berger G, et al. Structural brain
imaging evidence for multiple pathological processes at different stages of brain
development in schizophrenia. Schizophr Bull. julio de 2005;31(3):672-96.

47. Navari S, Dazzan P. Do antipsychotic drugs affect brain structure? A systematic and critical
review of MRI findings. Psychological Medicine. noviembre de 2009;39(11):1763-77.

48. Kim NR, Park SW, Lee JG, Kim YH. Protective effects of olanzapine and haloperidol on
serum withdrawal-induced apoptosis in SH-SY5Y cells. Progress in Neuro-
Psychopharmacology and Biological Psychiatry. 1 de abril de 2008;32(3):633-42.

49. Woods BT. Is Schizophrenia a Progressive Neurodevelopmental Disorder? Toward a
Unitary Pathogenetic Mechanism. AJP. diciembre de 1998;155(12):1661-70.

50. Haijma SV, Van Haren N, Cahn W, Koolschijn PCMP, Hulshoff Pol HE, Kahn RS. Brain
Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects. Schizophrenia
Bulletin. 1 de septiembre de 2013;39(5):1129-38.

51. Gassó P, Mas S, Molina O, Bernardo M, Lafuente A, Parellada E.
Neurotoxic/neuroprotective activity of haloperidol, risperidone and paliperidone in
neuroblastoma cells. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 10
de enero de 2012;36(1):71-7.

52. Dean CE. Antipsychotic-associated neuronal changes in the brain: Toxic, therapeutic, or
irrelevant to the long-term outcome of schizophrenia? Progress in Neuro-
Psychopharmacology and Biological Psychiatry. 1 de marzo de 2006;30(2):174-89.

53. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S.
Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-
analysis of longitudinal MRI studies. Neurosci Biobehav Rev. septiembre de
2013;37(8):1680-91.

54. Zipursky RB, Reilly TJ, Murray RM. The Myth of Schizophrenia as a Progressive Brain
Disease. Schizophrenia Bulletin. noviembre de 2013;39(6):1363-72.

55. Becker HE, Nieman DH, Wiltink S, Dingemans PM, van de Fliert JR, Velthorst E, et al.
Neurocognitive functioning before and after the first psychotic episode: does psychosis
result in cognitive deterioration? Psychol Med. octubre de 2010;40(10):1599-606.

56. Dickson H, Laurens KR, Cullen AE, Hodgins S. Meta-analyses of cognitive and motor
function in youth aged 16 years and younger who subsequently develop schizophrenia.
Psychol Med. abril de 2012;42(4):743-55.

57. Zabala A, Eguiluz JI, Segarra R, Enjuto S, Ezcurra J, Elizagarate E, et al. Course of
cognitive functioning in first-episode psychosis: a comparison between schizophrenia and
non schizophrenia psychosis. Rev Psiquiatr Salud Ment. diciembre de 2008;1(1):18-25.

58. Kawai N, Yamakawa Y, Baba A, Nemoto K, Tachikawa H, Hori T, et al. High-dose of
multiple antipsychotics and cognitive function in schizophrenia: The effect of dose-
reduction. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 30 de agosto
de 2006;30(6):1009-14.

59. Tronchin G, Akudjedu TN, Kenney JP, McInerney S, Scanlon C, McFarland J, et al.
Cognitive and Clinical Predictors of Prefrontal Cortical Thickness Change Following First-
Episode of Psychosis. Psychiatry Research: Neuroimaging. 30 de agosto de
2020;302:111100.

60. Zhang X, Yao J, Lv Y, Zhao X, Li Y, Sui Y, et al. An Association Study on the Cognitive
Function and the Cerebral Grey Matter Volume of Patients with First-Episode
Schizophrenia. Shanghai Arch Psychiatry. 25 de junio de 2018;30(3):154-67.

61. Shen X, Jiang F, Fang X, Yan W, Xie S, Zhang R. Cognitive dysfunction and cortical
structural abnormalities in first-episode drug-naïve schizophrenia patients with auditory
verbal hallucination. Front Psychiatry. 2022;13:998807.

62. Gutiérrez-Galve L, Wheeler-Kingshott CAM, Altmann DR, Price G, Chu EM, Leeson VC,
et al. Changes in the Frontotemporal Cortex and Cognitive Correlates in First-Episode
Psychosis. Biol Psychiatry. 1 de julio de 2010;68(1):51-60.

63. Fusar-Poli P, Papanastasiou E, Stahl D, Rocchetti M, Carpenter W, Shergill S, et al.
Treatments of Negative Symptoms in Schizophrenia: Meta-Analysis of 168 Randomized
Placebo-Controlled Trials. Schizophr Bull. julio de 2015;41(4):892-9.

64. Austin SF, Mors O, Budtz-Jørgensen E, Secher RG, Hjorthøj CR, Bertelsen M, et al. Long-
term trajectories of positive and negative symptoms in first episode psychosis: A 10 year
follow-up study in the OPUS cohort. Schizophrenia Research. 1 de octubre de
2015;168(1):84-91.

65. Stan AD, Tamminga CA, Han K, Kim JB, Padmanabhan J, Tandon N, et al. Associating
Psychotic Symptoms with Altered Brain Anatomy in Psychotic Disorders Using
Multidimensional Item Response Theory Models. Cereb Cortex. mayo de 2020;30(5):2939-
47.

66. Pearlson GD, Petty RG, Ross CA, Tien AY. Schizophrenia: a disease of heteromodal
association cortex? Neuropsychopharmacology. enero de 1996;14(1):1-17.

67. Liao J, Yan H, Liu Q, Yan J, Zhang L, Jiang S, et al. Reduced paralimbic system gray
matter volume in schizophrenia: Correlations with clinical variables, symptomatology and
cognitive function. J Psychiatr Res. junio de 2015;65:80-6.

68. Grinchii D, Dremencov E. Mechanism of Action of Atypical Antipsychotic Drugs in Mood
Disorders. Int J Mol Sci. 15 de diciembre de 2020;21(24):9532.

69. Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F. The therapeutic role of 5-
HT1A and 5-HT2A receptors in depression. J Psychiatry Neurosci. julio de
2004;29(4):252-65.

70. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: their key role in drugs to
treat schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. octubre de
2003;27(7):1159-72.

71. Bernstein HG, Steiner J, Guest PC, Dobrowolny H, Bogerts B. Glial cells as key players in
schizophrenia pathology: recent insights and concepts of therapy. Schizophr Res. enero de
2015;161(1):4-18.

72. Goudriaan A, de Leeuw C, Ripke S, Hultman CM, Sklar P, Sullivan PF, et al. Specific glial
functions contribute to schizophrenia susceptibility. Schizophr Bull. julio de
2014;40(4):925-35.

73. Almeida PGC, Nani JV, Oses JP, Brietzke E, Hayashi MAF. Neuroinflammation and glial
cell activation in mental disorders. Brain Behav Immun Health. febrero de 2020;2:100034.

703